Amedisys Management
Management criteria checks 1/4
Amedisys' CEO is Richard Ashworth, appointed in Apr 2023, has a tenure of 1.75 years. total yearly compensation is $16.97M, comprised of 4.1% salary and 95.9% bonuses, including company stock and options. directly owns 0.31% of the company’s shares, worth $9.38M. The average tenure of the management team and the board of directors is 1.8 years and 5.2 years respectively.
Key information
Richard Ashworth
Chief executive officer
US$17.0m
Total compensation
| CEO salary percentage | 4.1% |
| CEO tenure | 1.8yrs |
| CEO ownership | 0.3% |
| Management average tenure | 1.8yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Final Push For Amedisys As UnitedHealth Awaits Regulatory Clearance
Nov 05Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?
Apr 10
Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?
Feb 25Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around
Feb 10At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?
Jan 03A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)
Dec 16Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal
Nov 12Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?
Sep 19An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued
Sep 04Amedisys: ROIC, Tangible Book Value Each Softening
Aug 24Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement
Aug 04Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates
Jul 27We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt
Jul 20At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?
Jun 04Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled
May 05Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?
Apr 20Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?
Apr 06Is Amedisys (NASDAQ:AMED) A Risky Investment?
Feb 20Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue
Jan 19Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?
Dec 03These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely
Nov 18Amedisys (NASDAQ:AMED) Could Easily Take On More Debt
Aug 18Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)
Jul 23Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity
Jul 18Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive
Jun 28It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package
Jun 02Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?
May 24CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$83m |
| Jun 30 2024 | n/a | n/a | US$92m |
| Mar 31 2024 | n/a | n/a | -US$21m |
| Dec 31 2023 | US$17m | US$692k | -US$10m |
Compensation vs Market: Richard's total compensation ($USD16.97M) is above average for companies of similar size in the US market ($USD6.65M).
Compensation vs Earnings: Insufficient data to compare Richard's compensation with company performance.
CEO
Richard Ashworth (49 yo)
1.8yrs
Tenure
US$16,974,025
Compensation
Mr. Richard M. Ashworth is serving as Director of Rite Aid Corporation from December 2024. He served as Director at Tivity Health, Inc. since June 1, 2020 until April 2023 and had been its President since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.8yrs | US$16.97m | 0.31% $ 9.4m | |
| Executive VP | 7.3yrs | US$4.45m | 0.077% $ 2.3m | |
| Chief Compliance Officer | 5.3yrs | US$1.28m | no data | |
| Chief Strategy Officer | no data | US$1.37m | 0.0065% $ 196.5k | |
| Chief Accounting Officer & Principal Accounting Officer | 1.4yrs | no data | 0.0097% $ 292.3k | |
| CTO & Senior VP of Business Operations Systems | no data | no data | no data | |
| Acting Chief Information Officer | less than a year | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 9yrs | no data | 0.044% $ 1.3m | |
| VP of Marketing & Communications & Media Relations | no data | no data | no data | |
| Acting Chief People Officer | less than a year | no data | no data | |
| Senior Vice President of Development | no data | no data | no data |
1.8yrs
Average Tenure
47.5yo
Average Age
Experienced Management: AMED's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.8yrs | US$16.97m | 0.31% $ 9.4m | |
| Chairman | 10.1yrs | US$4.00m | 1.33% $ 40.3m | |
| Independent Director | 9.8yrs | US$267.62k | 0.063% $ 1.9m | |
| Independent Director | 5.2yrs | US$277.62k | 0.020% $ 595.1k | |
| Independent Director | 5.2yrs | US$267.62k | 0.017% $ 503.0k | |
| Lead Independent DIrector | 8.8yrs | US$282.62k | 0.039% $ 1.2m | |
| Independent Director | 8.8yrs | US$267.62k | 0.018% $ 550.7k | |
| Independent Director | 5.2yrs | US$272.62k | 0.020% $ 595.1k | |
| Independent Director | 4.1yrs | US$252.62k | 0.013% $ 390.5k |
5.2yrs
Average Tenure
63yo
Average Age
Experienced Board: AMED's board of directors are considered experienced (5.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 22:58 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Amedisys, Inc. is covered by 32 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Hoffman | Avondale Partners |
| Matthew Gillmor | Baird |
| Steven Valiquette | Barclays |